Pharmaceutical partners submitted bid to the FDA for vaccine to be reviewed and emergency authorization may occur within weeks
It could take as little as three weeks for US regulators to approve Pfizer and partner BioNTech’s emergency authorization request for their Covid-19 vaccine – with the first Americans being offered the first inoculation outside clinical trials in early December.
The major turning point in the worsening coronavirus pandemic came on Friday morning when the pharmaceutical partners submitted their bid to the Food and Drug Administration (FDA) for their vaccine to be reviewed.
